| Cancer type |
Study or subgroup |
Study type |
CIK group vs control group (n) |
CIK cells per infusion(×109) |
PFS% (month/year) |
OS% (month /year) |
MPFS(month) |
MOS(month) |
| Hepato -cellular carcinoma |
Hao MZ 2010 [96] |
Retrospective |
72 vs 74 |
10-50 |
6m/1y/2y: 72.2/40.4/25.3 vs 34.8/7.7/2.6(P<0.001) |
6m/1y/2y: 90.3/71.9/62.4 vs74.6/62.8/18.8(P<0.001) |
— |
31 vs 10(P<0.001) |
| Pan K 2013 [97] |
Retrospective |
204 vs 206 |
10-50 |
— |
1y/2y/3y/4y/5y: 93.6/83.3/76.6/71.1 vs 84.0/69.2/61.6/56.9/50.2(P=0.0007) |
— |
— |
| Huang ZM 2013 [98] |
Retrospective |
85 vs 89 |
Unclear |
1y/3y/5y:54.7/28.7/19.1 vs 34.7/7.0/0.0(P<0.001) |
1y/3y/5y/10y: 83.5/62.7/44.0/12.6 vs 76.4/40.4/23.7/0.0(P<0.05) |
17 vs10(P<0.001) |
56 vs 31(P=0.023) |
| Yu X 2014 [99] |
Phase II |
66 vs 66 |
7.2-12.1 |
— |
1y/2y/3y:74.2/53.0/42.4 vs50.0/30.3/24.2(P<0.05) |
— |
— |
| Cui J 2014 [100] |
Retrospective |
30 vs 32 |
1.0-2.0 |
— |
1y/2y: 100/100 vs 92.6/76.6(P<0.05) |
Undefined vs 12 |
— |
| Lee JH 2015 [101] |
Phase III |
115 vs 115 |
6.4±2.1 |
— |
— |
44.0 vs 30.0(P=0.010) |
— |
| Pan QZ 2015 [102] |
Retrospective |
511 vs 520 |
10-15 |
1y/3y/5y:54.0/37.8/33.0 vs 49.4/29.9/25.9(P=0.014) |
1y/3y/5y:82.4/60.0/47.5 vs 74.4/46.6/38.1(P=0.001) |
16 vs 12(P=0.014) |
41 vs 28(P=0.001) |
| Gastric cancer |
Jiang JT 2010 [103] |
Retrospective |
75 vs 81 |
1 |
— |
2y/5y:73.5/40.4 vs 52.6/23.9(P<0.05) |
— |
49 vs 27(P=0.007) |
| Shi L 2012 [104] |
Retrospective |
74 vs 77 |
1 |
3y/5y:47.3/28.3 vs 36.4/10.4(P=0.044) |
3y/5y: 67.6/32.4 vs 54.5/23.4(P=0.071) |
— |
— |
| Zhao H 2013 [105] |
Retrospective |
53 vs 112 |
5 |
3y: 54.7 vs 33.0(P=0.076)5y: 49.1 vs 24.1(P=0.026) |
3y: 62.3 vs 46.4(P=0.201)5y: 56.6 vs 26.8(P=0.014) |
36 vs 23(P=0.028) |
— |
| Liu H 2013 [106] |
Retrospective |
51 vs 47 |
1 |
— |
1y/2y/3y:98.0/92.2/72.5 vs 93.6/78.7/59.6(P<0.005) |
— |
— |
| Renal cell carcinoma |
Liu L 2012 [107] |
Phase II |
74 vs 74 |
7.6-11.4 |
3y: 18 vs 12(P=0.031) |
3y: 61 vs 23(P<0.001) |
12 vs 8(P=0.024) |
46 vs 19(P<0.001) |
| Wang ZX 2014 [108] |
Meta-analysis |
156 vs 144 |
— |
— |
1y: 94 vs 80(P=0.0002)2y: 81 vs 63(P<0.0001) |
— |
— |
| Lung cancer |
Li R 2012 [109] |
Phase II |
87 vs 87 |
13.07±1.37 |
3y: 39 vs 32(P=0.050)* |
3y: 61 vs 39(P=0.001) |
24 vs 12(P=0.028) |
48 vs 18(P=0.001) |
| Zhang J 2015 [110] |
Retrospective |
60 vs 60 |
Unclear |
3y/5y: 44.7/26.8 vs 27/20(P=0.014) |
3y/5y:74/62 vs 52/37(P=0.006) |
24 vs 14(P=0.014) |
72 vs 44(P=0.006) |
| Colorectal carcinoma |
Zhu Y 2013 [111] |
Retrospective |
21 vs 75 |
3 |
1y/2y: 89.47/59.65 vs 75.88/29.3(P=0.034) |
— |
— |
— |
| Zhang J 2014 [112] |
Retrospective |
30 vs 30 |
Unclear |
— |
— |
25.8 vs 12.0(P=0.001) |
41.3 vs 30.8(P=0.037) |
| Ovarian cancer |
Liu J 2014 [113] |
Retrospective |
46 vs 46 |
11.82±1.61 |
1y/2y/3y: 95.7/78.3/52.8 vs 91.3/45.7/21.7(P=0.004) |
3y: 86.1 vs 83.3(P=0.289) |
37.7 vs 22.2(P=0.004) |
61.5 vs 55.9(P=0.289) |
| Breast cancer |
Pan K 2014 [114] |
Retrospective |
45 vs 45 |
8.7-12.0 |
1y/2y/3y/4y:97.7/90.1/83.4/75.2 vs 88.9/64.4/62.1/56.4(P=0.0382) |
1y/2y/3y/4y: 100/100/96.7/92.4 vs 95.6/88.6/76.3/72.7(P=0.0046) |
— |
— |
| Nasopharyngeal carcinoma |
Li JJ 2012 [115] |
Randomly |
30 vs 30 |
1.25-18.2 |
1y/2y:24/12 vs 23/5(P=0.0234) |
1y/2y:27/21 vs 25/15(P=0.1347) |
26.93 vs 19.90(P=0.0234) |
Undefined vs 23 |
| Melanoma |
Han GL 2012 [116] |
Retrospective |
38 vs 114 |
11.57±2.45 |
— |
1y: 86.8 vs 74.6(P=0.097)3y: 76.3 vs 46.5(P=0.001)y: 71.1 vs 43.9(P=0.004) |
— |
Undefined vs 20.1(P=0.004) |
| Pancreatic cancer |
Wang M 2013 [117] |
Randomly |
29 vs 29 |
Unclear |
— |
— |
2.9 vs 2.5 (P=0.037) |
6.6 vs 6.1(P=0.09) |
| VS: versus; PFS: Progression Free Survival; OS: Overall Survival; MPFS: Median Progression Free Survival; MOS: Median Overall Survival; Unclear: not mentioned in the article; Undefined: There are still alive patients until follow-up due date; *: Different p value in Early (I-IIIA) stage group (P=0.259) and Advanced (IIIB-IV) stage group (P<0.001) |
